These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure. Packer M, Lee WH. Am J Cardiol; 1986 Feb 01; 57(4):347-8. PubMed ID: 3004185 [No Abstract] [Full Text] [Related]
28. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success]. Borghi C, Cosentino E, De Sanctis D. Ital Heart J Suppl; 2005 Dec 01; 6(12):769-79. PubMed ID: 16444921 [Abstract] [Full Text] [Related]
29. Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane. Guazzi M, Agostoni P. Clin Sci (Lond); 1999 Jan 01; 96(1):17-22. PubMed ID: 9857102 [Abstract] [Full Text] [Related]
30. Distinctive properties of perindopril among converting enzyme inhibitors in congestive heart failure. Sami MH. Can J Cardiol; 1994 Nov 01; 10 Suppl D():13D-16D. PubMed ID: 7954033 [Abstract] [Full Text] [Related]
35. Side effects of angiotensin converting enzyme inhibitor (captopril) in newborns and young infants. Gantenbein MH, Bauersfeld U, Baenziger O, Frey B, Neuhaus T, Sennhauser F, Bernet V. J Perinat Med; 2008 Nov 01; 36(5):448-52. PubMed ID: 18605972 [Abstract] [Full Text] [Related]